Sagimet Prices $115M Offering at $10.00 — Net Proceeds $107.5M to Fund Phase 3 Acne Trial
SGMT has more than doubled off its 52-week low of $4.5 on elevated volume (4.5× avg).
Summary
Sagimet priced a $115M underwritten offering at $10.00 per share, raising ~$107.5M net to fund its Phase 3 acne trial and pipeline development. The deal includes 2.75M pre-funded warrants and a 45-day lock-up. The underwriting agreement was signed with Leerink, TD Securities, Guggenheim, and Oppenheimer as joint book-runners, with Canaccord, H.C. Wainwright, JonesTrading, and Clear Street as co-leads, and closing was expected October 1, 2026.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — Underwriting agreement signed with Leerink, TD Securities, Guggenheim, Oppenheimer as joint book-runners; Canaccord, H.C. Wainwright, JonesTrading, Clear Street as co-leads; closing expected October 1, 2026.
Key Events · Financing and Capital Events · SGMT
-
New · · SEC 8-K
Underwriting Agreement Signed
The underwriting agreement was signed with Leerink, TD Securities, Guggenheim, and Oppenheimer as joint book-runners, and Canaccord, H.C. Wainwright, JonesTrading, and Clear Street as co-leads. Closing was expected October 1, 2026.
-
Offering Priced at $10.00
8,750,010 shares at $10.00 plus 2,750,010 pre-funded warrants at $9.9999, totaling $114,999,925 gross proceeds.
-
Net Proceeds $107.5M
After $6.9M underwriting discounts ($0.60 per share/warrant) and ~$0.6M expenses, net proceeds fund Phase 3 acne trial, pre-launch activities, TVB-3567 through Phase 2, and general corporate purposes.
-
Dilution of $4.87 Per Share
New investors pay $10.00 vs. as-adjusted net tangible book value of $5.13 per share, representing immediate dilution of $4.87 per share.
-
ATM Program Terminated
Prospectus supplement for the August 2025 ATM Program was terminated on September 30, 2026; Sales Agreement remains in force with no sales made under the ATM.
Analysis · SGMT · Life Sciences
A $115 million underwritten offering has been finalized, comprising 8.75M shares at $10.00 and 2.75M pre-funded warrants at $9.9999, with net proceeds of approximately $107.5 million. The capital will fund the U.S. Phase 3 acne trial for denifanstat, pre-launch activities, and TVB-3567 through Phase 2 topline results. Notably, the offering price sits above the September 29, 2026 last reported sale price of $9.33, indicating institutional demand. Existing shareholders face immediate dilution of $4.87 per share, but the raise extends cash runway well beyond the $257.6 million reported in Q2 2026. The company also terminated its ATM prospectus supplement on September 30, 2026, though the Sales Agreement remains in force with no sales made under that program. The underwriting agreement was signed with Leerink, TD Securities, Guggenheim, and Oppenheimer as joint book-runners, with Canaccord, H.C. Wainwright, JonesTrading, and Clear Street as co-leads, and closing was expected October 1, 2026.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 29.4% of the 1386 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.50%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SGMT was trading at $10.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $608.5M. The 52-week trading range was $4.50 to $11.45. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.